Correlations of complete blood count, liver enzyme and serum uric acid in Sudanese pre-eclamptic cases

Hind M. Beheiry1, Ibrahim A. Ali2, Mazin S. Abdalla3, Ahmed M. Sharif4, Amal M. Saeed4

1Department of Physiology, Faculty of Medicine, International University of Africa, Khartoum, Sudan
2Department of Physiology, Faculty of Medicine, The National Ribat University, Khartoum, Sudan
3Department of physiology, Faculty of Medicine, Napata College, Khartoum, Sudan
4Department of Medicine, Faculty of Medicine, University of Khartoum, Khartoum, Sudan

Received: 17 January 2018
Accepted: 28 February 2018

*Correspondence:
Dr. Hind Beheiry,
E-mail: hindbeheiry@hotmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Pre-eclampsia is a serious disorder of pregnancy with unknown ethological factors that may occur at any stage of second or third trimester of pregnancy. The objectives of the present study were to assess changes in complete blood counts including platelets, liver enzymes and serum uric acid in pre-eclamptic cases compared to second-half normal pregnant and non-pregnant Sudanese women and their correlations to other biomarkers.

Methods: This was a cross-sectional, case-control study performed from December 2008 to December 2010; in Omdurman Maternity Hospital, in concomitance with other studies in pre-eclampsia. The sample size included three groups, 72 up pre-eclamptic cases in their recent pregnancies, 96 normal pregnant in their second half of pregnancy and 33 non-pregnant (control) women; a total of 231 subjects. Questionnaire Interviews and clinical examination were done for all participants. Laboratory investigations were done including complete blood picture, liver enzymes and uric acid.

Results: The mean Hb concentration of the pre-eclamptic (11.3g/dl±1.7) was statistically significantly lower than that of the non-pregnant (12.1g/dl±0.2) (P=0.01) but not from that of the normal pregnant (11.4g/dl±0.1) (P=0.882). There was no statistical significant difference in the mean WBC count between the pre-eclamptic (7.4x10³/mm³±0.3) and non-pregnant (7.3x10³/mm³±0.3) (P=0.797) and between the pre-eclamptic and normal pregnant (7.7x10³/mm³±0.2) (P=0.270). There was a considerable statistical significant decrease in the mean platelets count of the pre-eclamptic cases (236.4x10³/mm³±8.3) compared to the non-pregnant group (322.0x10³/mm³±10.4) (P=0.0001) s well as to the normal pregnant (275.0x10³/mm³±8.9) (P = 0.003). In the pre-eclamptic cases, serum ALT correlated significantly with TWCC (r=0.26, P=0.03) and serum AST (r=0.65, P=0.000). In the pre-eclamptic cases, serum AST correlated significantly with Hb (r=0.26, P=0.03), serum ALT and serum uric acid (r=0.36, P=0.01).

Conclusions: There was a considerable statistical significant decrease in mean platelets count of the pre-eclamptic compared to the non-pregnant group and to the normal pregnant may be explained by hemodilution; whereas further decrease was due to pre-eclampsia. ALT and AST are strong prognostic indicators of pre-eclampsia.

Keywords: ALT, AST, CBC, Liver enzymes, Pre-eclampsia

INTRODUCTION

Pre-eclampsia is a diverse, multi-organ group of related disease processes. Pre-eclampsia occurs in 5%-8% of pregnancies after 20 weeks of gestation. The presentation is highly variable; but generally, includes the combination of maternal hypertension and proteinuria.

Pre-eclampsia is described as a new onset of hypertension (SBP ≥140 mm of Hg or DBP ≥90mm of Hg) and...
proteinuria (≥0.3g or 300mg protein in a 24-hour urine specimen or 1+ on dipstick) after 20 weeks of gestational age; it’s also referred to as toxemia of pregnancy.\textsuperscript{1} Severe pre-eclampsia is associated with pitting edema, headache, visual disturbances, and epigastric pain after 20\textsuperscript{th} week gestation.\textsuperscript{2,3} Pre-eclampsia is a leading cause of maternal and fetal morbidity and mortality in developing countries.\textsuperscript{5,5} The targeted organs are kidney, liver and brain which could be attributed to auto-intoxication; physiological derangement of the organs is self-evident.\textsuperscript{6} Reduction in utero-placental perfusion is considered as a major cause of fetal distress in pre-eclampsia.\textsuperscript{7,8}

Pre-eclampsia is a disorder in which a multitude of environmental, genetic as well as immunological factors intersect.\textsuperscript{9} There are several studies which suggested that platelets may play a major role in the etiopathogenesis of pre-eclampsia. Changes in coagulation system, in established pre-eclampsia, are well documented.\textsuperscript{10}

Among the hematological changes that occur in pre-eclampsia, thrombocytopenia is the most common. Thrombocytopenia is classically defined as a platelet count less than 150,000/cu mm.\textsuperscript{11} The pathogenesis of thrombocytopenia in pre-eclampsia is not clear. Although it is suggested that low platelet count in pre-eclampsia are associated with abnormal activation of coagulation system and accelerated platelet consumption.\textsuperscript{12}

Severe pre-eclampsia has been characterized by one or more of the following criteria: sustained systolic BP 160 mmHg or diastolic BP 110mmHg while on bed rest, nephrotic-range proteinuria, sudden oliguria, central nervous system disturbances, pulmonary edema or cyanosis, epigastric or right upper quadrant pain, liver dysfunction, thrombocytopenia, and fetal growth restriction.\textsuperscript{13,14}

Thus, severe pre-eclampsia may be diagnosed even with mildly elevated BP if there is other evidence of significant end organ disease. HELLP syndrome may or may not occur in conjunction with proteinuria or hypertension, although most patients will also have pre-eclamptic symptoms.\textsuperscript{15,16} HELLP syndrome is considered to be a severe form of disease, so its management may include prompt delivery of the fetus whether or not proteinuria or hypertension is present.

Uric acid (UA) has been associated for long time with pre-eclampsia, and it is of simple and inexpensive determination. Briefly, UA is the oxidation end product of purine metabolism in humans and higher primates, and its serum level results from the balance of endogenous production, dietary intake and elimination, which occurs for one-third through the gastro-enteric tract and for the remaining two-thirds through the kidney, by filtration and active secretion. Normal values in non-pregnant women of childbearing age, range from 3.0 to 6.0 mg/dl, lower than in men, as estrogens have a potent uricosuric effect.

Maternal mortality due to pre-eclampsia might be reduced through regular monitoring of platelet count and serum uric acid as a part of antenatal care routine check-up. Few studies are done in this area in Sudan. Therefore, the present study was designed to assess the association of complete blood count including platelets, liver enzymes and serum uric acid in pre-eclampsia.

**METHODS**

This was a cross-sectional, case-control and hospital-based study performed during a two-year period from December 2008 to December 2010; in Omdurman Maternity Hospital, in concomitance with other studies in pre-eclampsia. The objectives of the study were to assess changes in complete blood counts including platelets, liver enzymes and serum uric acid in pre-eclamptic cases compared to second-half normal pregnant and non-pregnant Sudanese women and their correlations to other biomarkers.

The samples selection was done by a systematic random selection every other day. It included three groups, 72 newly discovered and/or already diagnosed and followed-up pre-eclamptic cases in their recent pregnancies, 96 normal pregnant in their second half of pregnancy (20 weeks of pregnancy and onwards) and 63 non-pregnant (control) women; a total of 231 subjects. Selected participants were informed about the study; and their written consent was taken prior to admission into the antenatal ward for one day they were assured about the privacy of the data.

**Inclusion criteria**

- All the pregnant participants to be in the second half of pregnancy with regular follow-up cards and all the non-pregnant to have no history of diabetes mellitus, essential hypertension, renal disease or any other chronic disease.

**Exclusion criteria**

- Subjects with multiple pregnancies and/or have any obstetrical abnormality like placenta praevia, polyhydramnios

The enrolment of pregnant women for the study was performed by the assigned obstetricians in the antenatal care clinics. Questionnaire Interviews and clinical examination were done for all participants. Laboratory investigations were done including complete blood picture, liver enzymes and uric acid.

**Statistical analysis**

The data was analyzed by SPSS software R 9.0 (SPSS, Inv., Chicago, IL, USA) program Version 20, with the use of Spearman’s test, t-student, Chi-square,
RESULTS

Platelets count (/mm$^3$)

There was a considerable statistical significant decrease in the mean platelets count of the pre-eclamptic (236.4/mm$^3$±8.3) compared to the non-pregnant group (322.0/mm$^3$±10.4) (P=0.0001) as well as to the normal pregnant (275.0/mm$^3$±8.9) (P = 0.003) (Tables 1 and 2 respectively) (Figure 1).

Hemoglobin (g/dl) levels

The mean Hb concentration showed limited variation in values in the three groups. The mean Hb concentration of the pre-eclamptic (11.3g/dl±1.5) was statistically significantly lower than that of the non-pregnant (12.1g/dl±0.2) (P=0.01) but not from that of the normal pregnant (11.4g/dl±0.1) (P=0.882) (Tables 1 and 2 respectively) (Figure 2).

Table 1: Comparisons of means between the non-pregnant and pre-eclamptic cases.

| Category of participant | Mean ± SE | P-value |
|-------------------------|-----------|---------|
| Hemoglobin              |           |         |
| Non-pregnant            | 12.1±0.2  | 0.005*  |
| Pre-eclampsia           | 11.3±1.5  |         |
| Platelets               |           |         |
| Non-pregnant            | 322.0±0.4 | 0.000*  |
| Pre-eclampsia           | 236.4±8.3 |         |
| Total WBC count         |           |         |
| Non-pregnant            | 7.3±0.3   | 0.797   |
| Pre-eclampsia           | 7.4±0.3   |         |

*P-value (< 0.05) is significant.

Table 2: Comparisons of means between the non-pregnant and pre-eclamptic cases.

| Category of participant | Mean ± SE | P-value |
|-------------------------|-----------|---------|
| Hemoglobin              |           |         |
| Pregnant                | 11.4±0.1  | 0.88    |
| Pre-eclampsia           | 11.3±1.5  |         |
| Platelets               |           |         |
| Pregnant                | 275.0±8.9 | 0.003*  |
| Pre-eclampsia           | 236.4±8.3 |         |
| Total WBC count         |           |         |
| Pregnant                | 7.7±0.2   | 0.27    |
| Pre-eclampsia           | 7.4±0.3   |         |
| Pre-eclampsia           | 0.342±0.01|         |

*P-value (< 0.05) is significant.

Figure 1: Histogram of platelets count (/mm$^3$) in the three groups.

Figure 2: Histogram of hemoglobin levels (g/dl) in the three groups.

White blood cells count (WBC) (x103/mm$^3$)

There was no statistical significant difference in the mean WBC count between the pre-eclamptic (7.4x103/mm$^3$±0.3) and non-pregnant (7.3x103/mm$^3$±0.3) (P=0.797) and between the pre-eclamptic and normal pregnant (7.7x103/mm$^3$±0.2) (P=0.270) (Tables 1 and 2 respectively).

Serum alanine aminotransferase (U/L) activity

Serum ALT of the normal pregnant group correlated significantly with serum AST (r=0.25, P=0.01). In the pre-eclamptic cases, serum ALT correlated significantly with TWCC (r=0.26, P=0.03) and serum AST (r=0.65, P=0.000).

Serum aspartate aminotransferase (U/L) activity

Serum AST of the normal pregnant group correlated significantly with serum ALT (r=0.26, P=0.000). In the pre-eclamptic cases, serum AST correlated significantly with Hb (r=0.26, P=0.03), serum ALT and serum uric acid (r=0.36, P=0.01).
Table 3: The correlations between the variables and displays the r and the p-values for the variables in the study.

| Correlation                  | SBP     | DBP     | MBP     | UP      | UTP (gm/L) | Hb      | platelets | Total WBC count | SAT (total protein) | Serum aspartate transferase | SUA (mmol/L) |
|------------------------------|---------|---------|---------|---------|------------|---------|-----------|-----------------|------------------------|--------------------------|---------------|
| Hb                           | CC 0.11 | -0.04   | 0.02    | -0.12   | -0.18      | 1.00    | -0.03     | -0.01           | -0.13                  | 0.15                     | 0.26          | 0.00         |
| P value                      | 0.381   | 0.728   | 0.859   | 0.325   | 0.155      | -       | 0.792     | 0.942           | 0.0268                  | 0.234                    | 0.033         | 0.986        |
| platelets                    | CC 0.29 | -0.11   | -0.24   | -0.11   | -0.13      | -0.03   | 1.00      | 0.29            | 0.18                   | -0.11                    | -0.12         | -0.14        |
| P value                      | 0.016   | 0.383   | 0.052   | 0.367   | 0.332      | 0.792   | -         | 0.014           | 0.147                  | 0.375                    | 0.331         | 0.246        |
| Total WBC count              | CC 0.12 | 0.08    | 0.11    | -0.14   | 0.03       | -0.01   | 0.29      | 1.00            | 0.23                   | 0.26                     | 0.00          | -0.07        |
| P value                      | 0.316   | 0.495   | 0.358   | 0.256   | 0.819      | 0.942   | -         | 0.059           | 0.034                  | 0.979                    | 0.535         |            |
| SAT                          | CC 0.639| 0.227   | 0.429   | 0.521   | 0.307      | 0.234   | 0.375     | 0.034           | 0.009                  | -                       | 0.00          | 0.569        |
| P value                      | 0.36/3  | 0.343   | 0.407   | 0.338   | 0.11       | 0.033   | 0.331     | 0.979           | 0.499                  | -                       | 0.002         |            |
| Serum aspartate transferase  | CC 0.16 | 0.22    | 0.22    | 0.17    | 0.29       | 0.00    | -0.14     | -0.07           | 0.497                  | 0.07                     | 0.36          | 1.00         |
| SUA (mmol/L)                 | CC 0.191| 0.066   | 0.072   | 0.165   | 0.023      | 0.986   | 0.246     | 0.535           | 0.00                   | 0.569                    | 0.002         | -           |

CC- Correlation coefficient, SBP- Systolic blood pressure, DBP- Diastolic blood pressure, MBP- Mean blood pressure, SAT-Serum alanine transferase, Hb- Hemoglobin, SUA- Serum uric acid, UTP- Urine total protein, SA- Serum albumin, UP- Urine protein

In reference to the earlier publication which investigated Cystatin C as a better indicator of the glomerular filtration rate, which concluded that, an increment in the levels of Cystatin C correlated positively with pregnancy and more so with pre-eclampsia. Cystatin C concentrations also were observed to correlate negatively with the serum album and positively with serum aspartate aminotransferase with significance. Serum cystatin C correlated with serum albumin (r=-0.41, P=0.0001), serum aspartate aminotransferase (r=0.26, P=0.03) and serum uric acid (r=0.60, P=0.0001) in the pre-eclamptic group.

**DISCUSSION**

Pre-eclampsia is a serious disorder of pregnancy with unknown ethological factors that may occur at any stage of second or third trimester of pregnancy.17,18

There was a considerable statistical significant decrease in mean platelets count of the pre-eclamptic (236.4 / mm3±8.3) compared to the non-pregnant group (322.0/mm3±10.4) (P=0.0001) and to the normal pregnant (275.0/mm3±8.9) (P = 0.003); this may be explained by hemodilution; whereas further decrease was due to pre-eclampsia.19

The mean Hb concentration showed limited variation in values in the three groups. The mean Hb concentration of the pre-eclamptic (11.3g/dl±1.7) was statistically significantly lower than that of the non-pregnant (12.1g/dl±0.2) (P=0.01) but not than from that of the normal pregnant (11.4g/dl±0.1) (P=0.882) this could be attributed to hemodilution in normal pregnancy.

Figure 3: Histogram of liver transaminase AST (U/L) in the three groups.

The correlation coefficient between the hemoglobin and the serum uric acid was 0.00 which signifies no correlation between the two variables. On the other hand, statistical significance between the following variables was observed. Platelets and systolic blood pressure (p=0.016); uric acid and serum albumin (p=0.000); uric acid and AST (p=0.002) and AST and hemoglobin (0.033).
In pre-eclampsia, the liver function tests are affected and are known signs of deterioration of the condition. ALT and AST are strong prognostic indicators of pre-eclampsia. The increment in their levels may indicate deterioration of the condition. In this study, both ALT and AST increased in the pre-eclamptic cases when compared to normal pregnant women.

CONCLUSION

This study revealed that further investigation of the relation between platelets dysfunction and preeclampsia needed to be done in the future and a question about the use of hematological profile as a screening program for pregnant ladies with obvious risk factors of preeclampsia or pregnancy induced hypertension (PIH) should be answered.

ACKNOWLEDGMENTS

Author were highly grateful to all those who volunteered to donate their blood when needed for this project.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Ethical approval was approved by the Research Committee (Faculty of Medicine, IUA). Permission was given from Omdurman Maternal Hospital to conduct the study for cases of pre-eclampsia and normal pregnant subjects.

REFERENCES

1. Mashiloane CD, Moodley J. Induction or Caesarean section for pre-term preeclampsia. J Obstet Gynecol. 2002;22(4):353-6.
2. American College of Obstetricians and Gynecologists. Diagnosis and management of preeclampsia and eclampsia. ACOG Practice Bulletin No.33. Obstet Gynecol. 2002;99:159-67. (Level III)
3. Reports of the National High Blood Pressure Education Program Working Group report on high blood pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1-S22.
4. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY. Williams Obstetrics 23rd Ed. New York: McGraw-Hill 2010;706-56.
5. Sibai, Dekkar G, Kupferminc M. Preeclampsia. Lancet. 2005;365(9461):785-99.
6. Duha D, Konar H. Textbook of Obstetrics Including Perinatology and Contraception. 5th ed. Culcutta: New Central Book Agency (p) ltd. 2001;234-55.
7. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and Risk of Cardiovascular Disease and Cancer in Later Life: Systematic Review and Meta-analysis. Obstet Anesth Digest. 2008;28(2);80.
8. Soloman CG, Seely EW. Preeclampsia-Searching for the cause. N Engl J Med. 2004;350(7):641-12.
9. Irgens HU, Roberts JM, Reiseter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after preeclampsia: population based cohort study Pre-eclampsia and cardiovascular disease later in life: who is at risk? BMJ. 2001;323(7323):1213-7.
10. Bonnar J, McNicol GP, Douglas AS. Mean platelet and red cell volume measurement to estimate the severity of hypertension in pregnancy. Br. M Journal. 1971;2:12.
11. Shehata N, Burrows R, Kelton JG. Gestational thrombocytopenia. Clin Obstet Gynecol. 1999;42:327-34.
12. Redman CWG, Bonnar J, Beilin L. Early platelet consumption in preeclampsia. BMJ. 1978;1:467-9.
13. Sibai BM, Caritis S, Hauth J. What we have learned about preeclampsia. Semin Perinatol. 2003;27(3):239-46.
14. Lindheimer MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. J Am Soc Hypertens. 2008;2(6):484-94.
15. American College of Obstetricians and Gynecologists (ACOG) Practice bulletin: Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002;99(1):159-67.
16. Rath W, Fischer T. The diagnosis and treatment of hypertensive disorders of pregnancy: New findings for the antenatal and inpatient care. Dtsch Arztebl Int. 2009;106(45):733-8.
17. Hasanzadeh M, Ayatollahi H, Farzadmia M, Ayati S, Khoob MK. Elevated plasma total homocysteine in preeclampsia. Saudi Med J. 2008;29:875-8.
18. Vahidroudsari F, Ayati S, Torabizadeh A, Ayatollahi H, Esmaeli H, Shahabian M. Serum calcium and magnesium concentration in preeclamptic and normal pregnancies; a comparative study. J Reprod Infertil. 2008;9:256-62.
19. Hladunewich M, Karumanich SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol. 2007;2(3):543-9
20. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592-4.
21. Beheiry HM, Rayis DR, Elzibair AM, Omer MI, Makwana P, Saeed AM. Evaluation of Serum Cystatin C as an Indicator of Glomerular Filtration Rate and its Correlations to other Biomarkers in Detection of Pre-eclampsia. J Afr Ass Physiol. Sci.2015;3(2);199-206.

Cite this article as: Beheiry HM, Ali IA, Abdalla MS, Sharif AM, Saeed AM. Correlations of complete blood count, liver enzyme and serum uric Acid in Sudanese pre-eclamptic cases. Int J Reprod Contracept Obstet Gynecol 2018;7:1308-12.